

Technical Data Sheet

InVivoSIM bispecific anti-human PD-1 x VEGF-A (Ivonescimab Biosimilar)



bioxccl.com

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxccl.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: SIMB0107
Clone: Ivonescimab
Isotype: Human IgG1, κ , ScFv
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Mutations: L234A/L235A
Reported Applications: *in vivo* functional assays
in vitro functional assays
ELISA
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤ 0.5 EU/mg (≤ 0.0005 EU/ μ g)
Determined by LAL assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: 0.2 μ m filtration
Production: Purified from cell culture supernatant in an animal-free facility
Purification: Protein A
Molecular Weight: 150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Ivonescimab biosimilar antibody uses the same variable regions as the therapeutic antibody Ivonescimab, making it ideal for research use. Ivonescimab is a humanized, tetravalent bispecific IgG1-based antibody that simultaneously targets human PD-1 and VEGF-A. Its symmetric IgG-scFv architecture consists of an anti-VEGF-A IgG backbone with anti-PD-1 single-chain variable fragments (scFvs) fused to the C-termini of the heavy chains, providing two VEGF-A- and two PD-1-binding sites. By simultaneously blocking PD-1 checkpoint signaling and neutralizing VEGF-A, Ivonescimab combines immune checkpoint inhibition with suppression of VEGF-mediated angiogenesis and immunosuppression. The tetravalent architecture is designed to promote cooperative target engagement within the tumor microenvironment, where VEGF-A concentrations are elevated, potentially enhancing PD-1 blockade at sites of disease. This Ivonescimab biosimilar is well suited for studying PD-1 biology, VEGF-mediated angiogenesis, immune-vascular crosstalk, tumor microenvironment remodeling, dual checkpoint/anti-angiogenic strategies, and for benchmarking the therapeutic antibody's mechanism of

action and activity in pre-clinical experimental systems.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit [?utm_source=cr9k1b#tab_references](https://bioxcell.com/references/?utm_source=cr9k1b#tab_references) or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © Bio X Cell, LLC